AC Immune (NASDAQ:ACIU) Issues Earnings Results

AC Immune (NASDAQ:ACIU) issued its earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02, Zacks reports. AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. The company had revenue of $0.95 million during the quarter, compared to analysts’ expectations of $0.81 million.

AC Immune Stock Performance

Shares of NASDAQ:ACIU traded down $0.20 during trading on Thursday, reaching $3.23. The company had a trading volume of 55,842 shares, compared to its average volume of 190,952. The firm’s fifty day moving average is $2.88 and its 200 day moving average is $2.27. The firm has a market capitalization of $323.92 million, a PE ratio of -5.59 and a beta of 1.58. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.00.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ACIU shares. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Tuesday. Zacks Research upgraded shares of AC Immune from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Trading of AC Immune

A hedge fund recently raised its stake in AC Immune stock. Acadian Asset Management LLC lifted its stake in AC Immune (NASDAQ:ACIU) by 87.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 371,177 shares of the company’s stock after acquiring an additional 172,796 shares during the period. Acadian Asset Management LLC owned 0.37% of AC Immune worth $679,000 as of its most recent filing with the Securities and Exchange Commission. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.